SURF News and Press, Surface Oncology Inc. From 11/10/20

Surface Oncology (SURF): Q3 GAAP EPS of -$0.39.As of September 30, 2020, cash, cash equivalents and marketable securities were $102.5 million, compared to $105.2 million on December 31, 2019.The company continues to project that current cash and cash equivalents are sufficient to fund th...

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third qu...

CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D...

SRF388 inhibit s hepatocellular carcinoma tumor growth as a single agent in a preclinical model SRF114 induces destruction of tumor Tregs through antibody-dependent cellular cytotoxicity CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE...

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking a...

United Micro Corporation (UMC), Wipro Limited (WIT), CimbaBay Therapeutics (CBAY), Pacific Ethanol (PEIX) and Surface Oncology (SURF) are five stocks, under $10, that are rated "Strong Buys" and should continue to see gains in 2021. Plenty of tech stocks and other growth-oriented stocks ...

Palm Beach, FL – October 13, 2020 – The number of new cases of brain cancer across the world has been growing consistently for years and it is projected to continue on this upward path, which leads to recent reports projecting that the global treatment markets should also see ...

Shares of Surface Oncology (NASDAQ: SURF) were soaring 19.1% higher as of 3:26 p.m. EDT on Monday. The big jump came after StreetInsider reported that Surface Oncology has hired an investment bank to explore selling the company, with GlaxoSmithKline (NYSE: GSK) expressing in...

Surface Oncology ([[SURF]], +16%) is climbing sharply on a report that its exploring a sale.The company received a takeover approach from GlaxoSmithKline ([[GSK]], -0.1%) and has hired an investment bank, StreetInsider reports.Surface Oncology wants bankers to look for any other pos...

Gainers: iHuman (IH) +44%.Dillard's (DDS) +37%.Acorn International (ATV) +36%.Wah Fu Education (WAFU) +29%.Lizhi (LIZI) +29%.Apex Global Brands (APEX) +25%.WiMi Hologram Cloud (WIMI) +25%.Surface Oncology (SURF) +19%.Skillful Craftsman Education Technology (EDTK) +16%.Reliv' Internationa...